Welcome to our dedicated page for Travere Therapeutics SEC filings (Ticker: TVTX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Travere Therapeutics filings are most useful for verifying how rare-disease product approvals, clinical programs, operating expenses, and governance actions are documented in formal disclosures. The 8-K filings record financial results, FILSPARI regulatory events in FSGS and IgAN, pegtibatinase HARMONY Study updates, and management's discussion of GAAP and non-GAAP measures.
For TVTX, the most decision-useful disclosures are 8-K event filings tied to FDA actions and quarterly results, together with the DEF 14A proxy statement covering director elections, equity-plan authorization, executive-compensation votes, auditor ratification, and other governance matters.
Selected financial highlights (three and six months ended June 30, 2025): Total revenue was $114.4 million for Q2 and $196.2 million for the six months. Net product sales were $94.8 million in Q2 (FILSPARI $71.9M, tiopronin $23.0M) vs. $52.2M a year ago. License and collaboration revenue included a $17.5 million regulatory milestone. Operating loss for the quarter was $12.7M; six-month net loss was $53.98M (basic/diluted loss per share YTD $0.61). Cash and cash equivalents were $75.2M and available-for-sale marketable debt securities were $244.4M (total liquid investments $319.5M). Total assets were $555.3M, total liabilities $522.6M, and stockholders' equity $32.7M.
Operational and programmatic items: FILSPARI previously received full U.S. approval (Sept 5, 2024) and the European conditional MA converted to a standard MA in April 2025, triggering the $17.5M milestone in May 2025. The company submitted an sNDA seeking FSGS approval; the FDA accepted the sNDA and set a PDUFA date of Jan 13, 2026 and plans an advisory committee. Pegtibatinase enrollment is on a voluntary pause due to manufacturing scale-up issues. Renalys licensing and other collaborations remain active.